Skip to main content
UniHealth

Doctor search

Jeffrey B Cheng, MD

Dermatology · San Francisco

NPI 1699933069

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
9
1 carrier
Office
1
Since medical school
20 years
University of Texas Southwestern Medical School at Dallas, 2006

Offices

1 location · University of California San Francisco · 1,780 clinicians in this group

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

9 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cheng’s office at (415) 476-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026

California Medical Board record

Licence A102798 · Current

Licensed to practise in California · since 2008 · expires 2027-09-30 · University of Texas Southwestern Medical School at Dallas.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Dermatology - Dermatology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$28,855

Medicare paid this office $28,855 for 179 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)80$8,141$72
Destruction of precancer skin growth, 1 growth80$4,304$38
Short return visit (20+ min)64$3,996$49
New patient visit (45+ min)40$3,958$99
Destruction of skin growth, 1-14 growths45$3,399$53
See all 10 services
Every Original Medicare service billed
Return visit (30+ min)80$8,141$72
Destruction of precancer skin growth, 1 growth80$4,304$38
Short return visit (20+ min)64$3,996$49
New patient visit (45+ min)40$3,958$99
Destruction of skin growth, 1-14 growths45$3,399$53
New patient visit (30+ min)18$990$55
Destruction of precancer skin growth, 2-14 growths67$692$2
Biopsy of related skin growth, first growth29$510$17
Punch biopsy, first skin growth12$369$31
Short return visit11$345$29

Procedures Medicare counted

Procedure volume Medicare published
Melanoma (skin cancer) excision1-10None
Removal of skin lesions416More than 85% of doctors who do this
Removal or shaving of skin growth1-10None
Skin biopsy89More than 75% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Destruction of precancer skin growth, 2-14 growths167135285334356445
Destruction of precancer skin growth, 1 growth5335697177112
Destruction of skin growth, 1-14 growths162830414764
Biopsy of related skin growth, first growth201834202830
Punch biopsy, first skin growth–––11–12

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

179 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 15% · Women 48% · Also on Medicaid 32% · Health risk score 1.41. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 61% · Diabetes 28% · Coronary heart disease 26% · Chronic kidney disease 22% · Atrial fibrillation 21% · Cancer 19% · Depression 18% · Heart failure 17% · COPD 10% · Dementia 10% · Stroke 7%.

The office billed $320,969, Medicare allowed $43,889 and paid $28,855; for 981 services of 24 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024179981751.41$320,969$28,855
2023121722751.28$204,397$18,611
2022123693751.20$204,213$19,392
2021106615731.17$179,738$16,606
202083356741.24$110,694$9,289
201995436741.40$127,944$12,005
201877378741.52$104,515$9,129
201790362731.36$98,469$9,016
201669302721.44$75,445$7,168
201590308721.35$89,202$8,495
201475286711.26$68,190$6,508
201369205721.15$60,300$6,995

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 8 services

Original Medicare services billed in 2023
Short return visit (20+ min)75$5,228$51
Return visit (30+ min)31$3,144$75
Destruction of precancer skin growth, 1 growth57$2,901$38
Destruction of skin growth, 1-14 growths34$2,812$60
New patient visit (30+ min)14$1,031$74
Destruction of precancer skin growth, 2-14 growths50$555$2
Biopsy of related skin growth, first growth26$482$17
Short return visit14$418$23

2022: 10 services

Original Medicare services billed in 2022
Short return visit (20+ min)64$4,312$52
Return visit (30+ min)24$3,289$84
Destruction of precancer skin growth, 1 growth53$2,883$41
Destruction of skin growth, 1-14 growths31$1,988$48
New patient visit (45+ min)15$1,797$120
New patient visit (30+ min)23$1,467$64
Destruction of precancer skin growth, 2-14 growths42$611$2
Short return visit18$565$26
Biopsy of related skin growth, first growth19$377$19
Punch biopsy, first skin growth11$354$32

2021: 8 services

Original Medicare services billed in 2021
Short return visit (20+ min)60$3,880$53
Destruction of precancer skin growth, 1 growth53$2,708$39
Return visit (30+ min)18$2,428$84
Destruction of skin growth, 1-14 growths24$1,764$59
New patient visit (30+ min)20$1,211$61
Short return visit18$833$30
Biopsy of related skin growth, first growth32$571$17
Destruction of precancer skin growth, 2-14 growths41$496$2

2020: 6 services

Original Medicare services billed in 2020
Short return visit (20+ min)59$2,943$41
Destruction of skin growth, 1-14 growths20$1,748$62
Destruction of precancer skin growth, 1 growth31$1,469$42
New patient visit (15+ min)26$1,004$39
Biopsy of related skin growth, first growth16$305$17
Destruction of precancer skin growth, 2-14 growths23$246$2

2019: 6 services

Original Medicare services billed in 2019
Short return visit (20+ min)67$4,412$43
Destruction of precancer skin growth, 1 growth40$2,258$43
New patient visit (15+ min)28$1,232$44
Destruction of skin growth, 1-14 growths11$1,041$65
Biopsy of related skin growth, first growth19$411$21
Destruction of precancer skin growth, 2-14 growths30$333$2

2018: 5 services

Original Medicare services billed in 2018
Short return visit (20+ min)61$3,445$41
Destruction of precancer skin growth, 1 growth40$1,896$40
Biopsy of single growth of skin and/or tissue24$922$32
New patient visit (15+ min)15$609$41
Destruction of precancer skin growth, 2-14 growths33$286$2

2017: 5 services

Original Medicare services billed in 2017
Short return visit (20+ min)60$3,095$41
Destruction of precancer skin growth, 1 growth38$1,730$39
New patient visit (15+ min)33$1,447$44
Biopsy of single growth of skin and/or tissue27$758$25
Destruction of precancer skin growth, 2-14 growths28$258$2

2016: 5 services

Original Medicare services billed in 2016
Short return visit (20+ min)40$2,197$39
Destruction of precancer skin growth, 1 growth26$1,358$42
New patient visit (15+ min)30$1,129$38
Biopsy of single growth of skin and/or tissue17$611$34
Destruction of precancer skin growth, 2-14 growths22$239$2

2015: 7 services

Original Medicare services billed in 2015
New patient visit (15+ min)48$1,860$39
Short return visit (20+ min)31$1,510$40
Destruction of precancer skin growth, 1 growth30$1,490$44
Destruction of skin growth, 1-14 growths11$655$60
Biopsy of single growth of skin and/or tissue19$598$26
Short return visit16$343$20
Destruction of precancer skin growth, 2-14 growths22$203$2

2014: 6 services

Original Medicare services billed in 2014
Short return visit (20+ min)29$1,629$42
New patient visit (15+ min)32$1,302$41
Destruction of precancer skin growth, 1 growth19$932$41
Biopsy of single growth of skin and/or tissue23$780$34
Short return visit19$403$20
Destruction of precancer skin growth, 2-14 growths16$222$2

2013: 6 services

Original Medicare services billed in 2013
Short return visit (20+ min)35$1,937$40
New patient visit (15+ min)31$1,313$42
Destruction of precancer skin growth, 1 growth20$1,086$49
Biopsy of single growth of skin and/or tissue19$684$34
Short return visit12$283$20
Destruction of precancer skin growth, 2-14 growths17$190$4

Drugs they prescribed that Part D paid

$210,650

Pharmacies billed $210,650 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 373) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.

313 generic and 60 brand-name prescriptions · $210,650 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Dupixent24$89,056$3,711
Dupixent17$60,299$3,547
Fluocinonide42$1,664$40
Betamethasone Dipropionate24$1,508$63
Fluorouracil11$814$74
See all 11 drugs
Every Part D drug this clinician prescribed
Dupixent24$89,056$3,711
Dupixent17$60,299$3,547
Fluocinonide42$1,664$40
Betamethasone Dipropionate24$1,508$63
Fluorouracil11$814$74
Clobetasol Propionate21$571$27
Triamcinolone Acetonide41$267$7
Clotrimazole16$205$13
Ketoconazole15$198$13
Minoxidil12$174$14
Hydrocortisone52$167$3

Year by year

Part D prescribing by year
20243731270% (0)16%$210,650
2023236770% (0)17%$144,900
2022239820% (0)None$75,331
2021195690% (0)11%$17,031
2020117480% (0)13%$10,005
2019120450% (0)None$6,675
201893320% (0)13%$8,355
20176539None18%$6,860
201667300% (0)16%$11,638
201593390% (0)None$11,101
201496410% (0)26%$12,122
20138034None15%$5,543

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 9 drugs

Part D drugs prescribed in 2023
Dupixent19$64,050$3,371
Dupixent15$58,775$3,918
Betamethasone Dipropionate16$1,454$91
Fluocinonide18$1,228$68
Tacrolimus14$1,053$75
Clobetasol Propionate15$810$54
Triamcinolone Acetonide33$341$10
Ketoconazole20$304$15
Hydrocortisone23$150$7

2022: 7 drugs

Part D drugs prescribed in 2022
Betamethasone Dipropionate21$3,617$172
Fluocinonide31$2,063$67
Tacrolimus12$1,642$137
Doxycycline Hyclate12$986$82
Triamcinolone Acetonide30$344$11
Hydrocortisone23$179$8
Ketoconazole12$123$10

2021: 5 drugs

Part D drugs prescribed in 2021
Betamethasone Dipropionate19$3,449$182
Fluocinonide27$1,977$73
Clobetasol Propionate20$1,631$82
Triamcinolone Acetonide29$244$8
Hydrocortisone21$126$6

2020: 3 drugs

Part D drugs prescribed in 2020
Betamethasone Dipropionate11$1,109$101
Triamcinolone Acetonide28$288$10
Ketoconazole14$207$15

2019: 2 drugs

Part D drugs prescribed in 2019
Triamcinolone Acetonide28$312$11
Ketoconazole15$247$16

2018: 2 drugs

Part D drugs prescribed in 2018
Ketoconazole12$201$17
Triamcinolone Acetonide16$194$12

2016: 1 drug

Part D drugs prescribed in 2016
Clobetasol Propionate21$6,494$309

2015: 3 drugs

Part D drugs prescribed in 2015
Clobetasol Propionate25$5,725$229
Desonide15$1,419$95
Triamcinolone Acetonide20$295$15

2014: 4 drugs

Part D drugs prescribed in 2014
Clobetasol Propionate19$2,043$108
Desonide14$1,595$114
Triamcinolone Acetonide15$215$14
Ketoconazole11$190$17

2013: 3 drugs

Part D drugs prescribed in 2013
Desonide12$887$74
Clobetasol Propionate18$740$41
Triamcinolone Acetonide15$392$26

Money from drug and device companies

$39 in 2025

Industry payments by year
202512None$39
202312None$141
202211None$54
202112None$81
201911None$21

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
PfizerVyndaqel$39
2 payments
  • Meals for Vyndaqel · 2025-05-28 · $19
  • Meals for Vyndaqel · 2025-02-18 · $21
See all 2 published payments
Every published payment
PfizerMeals · 2025-05-28Vyndaqel$19
PfizerMeals · 2025-02-18Vyndaqel$21
See earlier years (2023, 2022, 2021, 2019)

2023: $141

Payments by company in 2023
Regeneron PharmaceuticalsDupixent$141
2 payments
  • Meals for Dupixent · 2023-08-16 · $46
  • Meals for Dupixent · 2023-05-16 · $95

2022: $54

Payments by company in 2022
Sun Pharmaceutical IndustriesNone$54
1 payment
  • Meals · 2022-08-10 · $54

2021: $81

Payments by company in 2021
Sun Pharmaceutical IndustriesIlumya$81
2 payments
  • Meals for Ilumya · 2021-10-13 · $50
  • Meals for Ilumya · 2021-08-17 · $31

2019: $21

Payments by company in 2019
AbbVieSkyrizi$21
1 payment
  • Meals for Skyrizi · 2019-09-12 · $21

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Janssen Research & Development, LLC · Immune Spatial Features of Guselkumab Cutaneous Response · 2025Their institution$176,668
Janssen Research & Development, LLC · Immune Spatial Features of Guselkumab Cutaneous Response · 2024Their institution$115,691
PFIZER INC. · Spatial Analysis of Alopecia Areata Inflammation · 2021Their institution$100,000
Janssen Research & Development, LLC · Immune Spatial Features of Guselkumab Cutaneous Response · 2023Their institution$64,483
PFIZER INC. · Spatial Analysis of Alopecia Areata Inflammation · 2023Their institution$28,750
PFIZER INC. · Spatial Analysis of Alopecia Areata Inflammation · 2022Their institution$28,750

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1699933069
Licence
CA A102798California A102798: Current · expires 2027-09-30
Trained
University of Texas Southwestern Medical School at Dallas, 2006 · 20 years ago
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X)
Mailing address
UCSF Dept of Dermatology, 1701 Divisadero St., 3rd Floor, San Francisco, CA, 94143
NPI first listed
2008-06-01
NPI last updated
2012-08-27

This is when the NPI record was last certified, not a medical board exam.